Alzheimer’s disease

View All

Alzheimer’s Disease Diagnostic Market Analysis
Alzheimer’s Disease Diagnostic: Market Dynamics, Key Trends, and Growth Potential

Alzheimer’s Disease represents one of the most pressing challenges in today's healthcare market. As its prevalence continues to soar with the aging global population, the hurdles in its diagnostic and treatment also continue to rise. As per the estimate, globally, about 55 million people are living with dementia in...

Find More

alzheimers-disease-treatment-drug-clinical-trial-failures
Challenges in the Pursuit of Alzheimer’s Disease Treatment Breakthroughs: Drug Clinical Trial Failures

Alzheimer’s, the most common type of dementia, particularly with an increasing geriatric population, presents a major global crisis. The disease mostly occurs in sexagenarians, but it may manifest in quadragenarians. It is one of the most prevalent neurodegenerative disorders with a multifactorial pathogenesis. It ...

Find More

Pharma News for AbbVie, BioArctic, Coherus
LEQEMBI Intravenous Infusion Approval; Novartis’ Presented Updates on Lutathera; FDA Accepts Submission to Add PH-ILD to YUTREPIA Label; FDA Issues CRL to BLA for Pegfilgrastim-cbqv; FDA Fast Track Designation to Therpay, MWTX-003; EC Approves TEPKINLY (epcoritamab) for R/R DLBCL

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera On Sept. 20, 2023, Disc Medicine, Inc. (NASDAQ: IRON) announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to MWTX-003 for the treatment of patients with Polycyt...

Find More

MedTech News for Quest, DuPont, BD
Quest Introduced Consumer-Initiated Blood Test for Alzheimer’s Disease Risk Assessment; DuPont Acquires Spectrum Plastics; BD Received 510(k) Clearance for Molecular Combination Test; Natera Updates on Phase III ALTAIR Trial of Signatera; Anteris’ DurAVR transcatheter heart valve Trial

Quest Introduced First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on Questhealth Website On July 31, 2023, Quest Diagnostics, a leader in diagnostic information services, announced the introduction of the AD-Detect™ Test for Alzheimer's Disease on questhealth.com – the first ...

Find More

Pharma News Astellas, Eisai, Iovance, Biophytis
FDA Grants Priority Review for Zolbetuximab BLA; FDA Traditional Approval for LEQEMBI for Alzheimer’s Disease; Iovance Announces Regulatory and Clinical Updates for TIL Therapy in Advanced NSCLC; Biophytis Seeks FDA Approval to Launch Phase 3 Study of Potential Treatment of Sarcopenia; Orphan Drug Designation to Marker Therapeutics’s MT-401 for AML Treatment; Axsome Therapeutics Initiates Phase 3 Trial of Solriamfetol for ADHD

Astellas Announces FDA Grants Priority Review for Zolbetuximab Biologics License Application Astellas Pharma Inc. announced that the FDA has accepted and granted Priority Review for the company's Biologics Licence Application (BLA) for zolbetuximab, a first-in-class investigational Claudin 18.2 (CLDN18.2)-target...

Find More

leqembi-for-alzheimers-disease-treatment
Leqembi: A New Hope for Alzheimer’s Disease Patients

Alzheimer’s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis ...

Find More

MedTech news for Eko. Haemonetics. Roche, Medtronic, Biodesix
GE HealthCare, DePuy Synthes Announced Collaboration; Eko Health Launched CORE 500 Digital Stethoscope; Haemonetics’s NexSys PCS Plasma Collection System; Roche’s Alzheimer’s Disease Cerebrospinal Fluid (CSF) Assays; Medtronic’s MiniMed 780G system; Biodesix’s VeriStrat Blood-Based Host Immune Classifier

GE HealthCare Announced Collaboration with DePuy Synthes to Bring Advanced 3D Precision Imaging Innovation to Spine Practices in the United States On June 21, 2023, GE HealthCare entered into a distribution agreement with DePuy Synthes, the Orthopaedics division of Johnson & Johnson, to bring GE HealthCare’s...

Find More

parkinsons-disease-psychosis-treatment
What Lies Ahead For Parkinson’s Disease Psychosis Treatment Market?

The term “psychosis” defines a group of mental symptoms that occur when there has been a partial loss of contact with reality. A person’s thoughts and perceptions are distorted during a psychotic episode, and they could find it difficult to distinguish between tangible and intangible. Other signs include nonsensica...

Find More

donanemab-for-alzheimers-disease-treatment
The Road Ahead for Donanemab: Will the Therapy be the Next Imminent Breakthrough in the Alzheimer’s Disease Treatment Landscape?

Alzheimer’s disease (AD) is becoming a rapidly growing public health concern due to the rise in the world’s aging population. Based on the data obtained from the 2019 Global Burden of Disease (GBD) database, the incidence and prevalence of Alzheimer’s disease and other dementias increased by 147.95 and 160.84%, res...

Find More

Pharma News and Updates for Luye Pharma, AstraZeneca, Oramed, Eisai, AbbVie
FDA Approves Luye’s Rykindo; EU Approves AstraZeneca’s Tezspire; Oramed Announces Trial Results of ORMD-0801; Eisai and Biogen File Lecanemab in the EU; AbbVie and Anima Biotech Announce Collaboration; AstraZeneca’s Avillion Receives FDA Approval

FDA Approves Luye Pharma’s Rykindo for Schizophrenia Luye Pharma has received its first FDA approval for Rykindo, an injectable formulation of the antipsychotic risperidone administered every two weeks. Rykindo has been approved by the US Food and Drug Administration for the treatment of schizophrenia as well as...

Find More